ReviewInternational journal of molecular sciences2023
Intestinal Behcet's Disease: A Review of the Immune Mechanism and Present and Potential Biological Agents.
Review in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.
- Pooled it
- A case report: an unusual case of ulcerative intestinal IgG4-related disease with clinical features overlapping with probable intestinal Behcet's disease.BMC gastroenterology · 2026Article
- Single-cell RNA sequencing of intestinal Behçet's disease identifies putative pathogenic programs and potential therapeutic targets.Biomolecules & biomedicine · 2026Article
- Biological therapies in paediatric Behçet's disease: results of an international collaborative study by the PRES Vasculitis Working Party.Rheumatology (Oxford, England) · 2026Article
- Successful Surgical Treatment of Pediatric Intestinal Behçet's Disease with Ileocecal Ulcer Refractory to Medical Therapy: A Case Report.Surgical case reports · 2026Article
- Intestinal Behçet's disease presenting with intestinal obstruction misdiagnosed as Crohn's disease: a case report.Journal of medical case reports · 2025Article
- Development and application of an artificial intelligence-assisted endoscopic system for automatic and accurate diagnosis of colorectal ulcers.International journal of colorectal disease · 2025Article
- Behçet's disease: incidence, prevalence, and real-word data on the use of biologic agents in Japan.Journal of gastroenterology · 2025Observational
- Intestinal ultrasound for intestinal Behçet disease reflects endoscopic activity and histopathological findings.Intestinal research · 2024Article
- Intestinal Behçet's disease: A review of clinical diagnosis and treatment.World journal of gastrointestinal surgery · 2024Article
- Case report: Successful remission with upadacitinib in a young patient with anti-TNF-refractory intestinal Behçet's disease.Frontiers in immunology · 2024Article
- Neutrophils in Inflammatory Diseases: Unraveling the Impact of Their Derived Molecules and Heterogeneity.Cells · 2023Review
- Solving the Puzzle: Molecular Research in Inflammatory Bowel Diseases.International journal of molecular sciences · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Behcet's disease (BD) is a chronic and recurrent systemic vasculitis involving almost all organs and tissues. Intestinal BD is defined as BD with predominant gastrointestinal involvement, presenting severe complications such as massive gastrointestinal hemorrhage, perforation, and obstruction in some cases. To some extent, intestinal BD is classified as a member of inflammatory bowel disease (IBD), as it has a lot in common with classical IBD including Crohn's disease (CD) and ulcerative colitis (UC). Certainly, the underlying pathogenesis is not the same and dysregulation of immune function is believed to be one of the main pathogeneses in intestinal BD, although the etiology has not been clear up to now. Biological agents are an emerging category of pharmaceuticals for various diseases, including inflammatory diseases and cancers, in recent decades. Based on the deep understanding of the immune mechanism of intestinal BD, biological agents targeting potential pathogenic cells, cytokines and pathways are optimized options. Recently, the adoption of biological agents such as anti-tumor necrosis factor agents has allowed for the effective treatment of patients with refractory intestinal BD who show poor response to conventional medications and are faced with the risk of surgical treatment. In this review, we have tried to summarize the immune mechanism and present potential biological agents of intestinal BD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.